Market Overview

UPDATE: Wedbush Lowers Medifast's PT

Related MED
10 Notable Stocks Trading Ex-Dividend Wednesday, September 21
Mid-Afternoon Market Update: Dow Jumps 200 Points; Bojangles Shares Climb Following Upbeat Earnings

According to a research report published this morning, Wedbush has lowered Medifast's (NYSE: MED) PT from $23 to $22.

In the report, Wedbush commented, "Return to double-digit growth in direct-selling business leads to revenue upside. Q1 revenues of $89 million exceeded the consensus estimate of $87 million on 13% growth in Take Shape for Life, the direct-selling arm, to $53 million, due to a 2% increase in active health coaches and 3% increase in productivity."

Wedbush maintains its Outperform rating on Medifast, which is currently trading at $16.57.

Latest Ratings for MED

Jan 2016WunderlichInitiates Coverage onHold
Nov 2015Sidoti & Co.DowngradesBuyNeutral
Oct 2015Sidoti & Co.UpgradesNeutralBuy

View More Analyst Ratings for MED
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Price Target Analyst Ratings


Related Articles (MED)

View Comments and Join the Discussion!